The Asia-Pacific antibody-drug conjugates (ADC) market was valued at USD 2.90 billion in 2025. It is estimated at USD 3.55 billion in 2026 and is projected to reach USD 17.81 billion by 2036, growing at a CAGR of 17.5% over the 2026-2036 forecast period. This report examines epidemiology, approved ADCs by country, the Asia-originated pipeline, Asia-to-global licensing, regulation, pricing and reimbursement, the CDMO base, and competition.
The study covers medicines in which a monoclonal antibody carries a highly potent drug payload attached by a chemical linker, as sold across the region's markets. Products are analyzed by target, payload, linker, and format, and the report separates ADCs developed by multinational companies from those that originated in China, Japan, and South Korea. Market value is based on manufacturer sales of approved products, on the same basis as the Meticulous global ADC study.
Asia is both a major source of patients and a growing source of new ADCs, with roughly half of the about 20 million new cancer cases diagnosed worldwide in 2022 occurring in Asia, according to the International Agency for Research on Cancer, and breast, lung, and gastric cancers, all key ADC indications, are among the most common tumors in the region. Japan's Daiichi Sankyo created Enhertu and Datroway on its DXd platform, keeps exclusive rights to both in Japan, and makes them for global supply. China has moved from fast follower to innovator, with the first TROP2 ADC approval in lung cancer in March 2025 and, as reported in June 2026, the world's first bispecific ADC approval for izalontamab brengitecan from Sichuan Baili and SystImmune.
Value growth is held back by the deep price cuts that China's National Healthcare Security Administration requires for reimbursement listing, regular national health insurance price revisions in Japan, and the low launch prices of domestic Chinese ADCs. In poorer markets such as India, Indonesia, and Vietnam, most patients pay out of pocket, which limits use. High-potency payload synthesis and conjugation are complex and capacity is concentrated, and toxicities such as interstitial lung disease, which has shown higher incidence among Japanese patients treated with trastuzumab deruxtecan, require close monitoring. Other challenges are U.S. legislative scrutiny of Chinese biotechnology companies and contract manufacturers, crowding around HER2 and TROP2, biosimilar entry as early ADC patents expire, and the need for multiregional data, since U.S. regulators have been reluctant to accept trials run only in China.
Opportunities include out-licensing of Asian ADC assets to global drug makers, as seen in deals signed by SystImmune, Kelun-Biotech, Hansoh, Duality Biologics, and LigaChem Biosciences with Western partners. Contract manufacturing is expanding through WuXi XDC in China and Samsung Biologics and Celltrion in South Korea, bispecific and dual-payload ADCs are advancing fastest in Asian pipelines, and biosimilars, lower-cost domestic products, and public insurance schemes could open access in India, Southeast Asia, and Australia. Key trends include China's growing role as a world source of new ADCs, the first bispecific approval, development focused on lung, gastric, and nasopharyngeal cancers that are common in Asia, and the dominance of topoisomerase I payloads.
By target, the study covers HER2, TROP2, Nectin-4, hematologic targets (CD30, CD79b, CD22, CD33, and BCMA), and EGFR/HER3 & emerging targets (B7-H3, c-Met, Claudin 18.2, and others). HER2 is expected to hold the largest share in 2026, supported by Enhertu's strong uptake in Japan and China following reimbursement listing, Kadcyla's established use, and domestic HER2 ADCs such as disitamab vedotin and trastuzumab rezetecan. EGFR/HER3 & emerging targets are expected to grow at the highest CAGR, driven by the June 2026 approval of the EGFR-HER3 bispecific izalontamab brengitecan and a deep pipeline of B7-H3, c-Met, and Claudin 18.2 candidates from Asian developers.
The payload analysis includes topoisomerase I inhibitors, microtubule inhibitors, DNA-damaging agents, and novel payloads. Topoisomerase I inhibitors are expected to lead in 2026, since Enhertu, Datroway, sacituzumab tirumotecan, and trastuzumab rezetecan all use this class, which kills nearby tumor cells with uneven target expression. Novel payloads are expected to grow at the highest CAGR, as Chinese and Korean developers test new payload classes and dual-payload designs to overcome resistance that builds up when similar ADCs are used one after another.
By linker, the report covers cleavable and non-cleavable linkers. Cleavable linkers are used in most recent launches in the region, including Enhertu, which relies on a tetrapeptide-based cleavable linker to release its DXd payload, and in the topoisomerase I-based products from Chinese developers. Non-cleavable linkers are used in established products such as Kadcyla and in biosimilar trastuzumab emtansine launched in India, giving this segment a stable base as biosimilar versions widen access.
By format, the market is divided into monospecific, bispecific, and dual-payload ADCs. Monospecific ADCs are expected to represent the largest share in 2026, because nearly every product now sold, from Enhertu to China's recent domestic launches, binds a single antigen. Bispecific ADCs are expected to grow at the highest CAGR, building on the first approval of a bispecific ADC in China in June 2026 and further Asian candidates that target two antigens to improve tumor selectivity and limit escape.
By product origin, the report covers multinational-originated ADCs and Asia-originated ADCs, with the latter split into China-, Japan-, and Korea-originated products. Multinational-originated ADCs are expected to hold the largest share in 2026, reflecting the broad use and reimbursement of Enhertu, Kadcyla, Padcev, Adcetris, and other established brands across Japan, China, South Korea, Australia, and Taiwan. Asia-originated ADCs are expected to grow at the highest CAGR, as China had approved five or more domestic ADCs by mid-2026, these products launch at lower prices, and they are steadily being added to reimbursement lists.
By indication, the study covers breast cancer (HER2-positive, HER2-low & HER2-ultralow, and triple-negative & HR-positive/HER2-negative), lung cancer (EGFR-mutant NSCLC, HER2-mutant NSCLC, and other NSCLC & SCLC), gastric cancer, urothelial cancer, hematologic malignancies, gynecologic cancers, and nasopharyngeal & other cancers. Breast cancer is expected to hold the largest share in 2026, as Enhertu, Kadcyla, Datroway, and sacituzumab tirumotecan are widely used across HER2-positive, HER2-low, and triple-negative disease. Lung cancer is expected to grow at the highest CAGR, driven by China's 2025 approvals in EGFR-mutant and HER2-mutant NSCLC and the high frequency of EGFR mutations among Asian patients.
By end user, the report covers public hospitals, private hospitals, and specialty cancer centers. Public hospitals are expected to account for the largest share in 2026, as public tertiary hospitals in China, Japan, and South Korea deliver most reimbursed cancer care, including Enhertu after its national listing in China. Specialty cancer centers are expected to grow at the highest CAGR, since ADC trials, toxicity management, and complex regimens are concentrated in leading centers, one of which, Shanghai Chest Hospital, ran the key trial for trastuzumab rezetecan.
Japan is expected to be the largest country market in the region in 2026, supported by universal health insurance, early approvals, high spending per patient, and Daiichi Sankyo's sole domestic rights to its two DXd brands. Astellas and Takeda co-market Padcev and Adcetris, and Chugai sells Roche's ADCs, giving Japan the most developed ADC market in Asia. South Korea is another important market, with national insurance coverage, active participation in global trials, and ADC know-how at LigaChem Biosciences, Samsung Biologics, and Celltrion.
China is expected to grow at the highest CAGR during the forecast period, driven by fast approval of domestic ADCs, reimbursement listing, and licensing income that funds further development. Australia & New Zealand offer steady growth through the Pharmaceutical Benefits Scheme and Pharmac, while India, which recorded about 1.46 million new cancer cases in 2022 according to the Indian Council of Medical Research, is growing from a smaller base as biosimilar trastuzumab emtansine and public insurance widen access. Taiwan, Singapore, and Southeast Asia add demand as reimbursement and cancer services expand.
The market brings together multinational drug makers, Japan's Daiichi Sankyo and its peers, fast-growing Chinese developers, Korean technology and manufacturing firms, and contract manufacturers. Companies compete on clinical differentiation, speed of regional approval, reimbursement listing and pricing, manufacturing capacity, and global partnerships. Main strategies include label expansion, reimbursement listing, out-licensing, next-generation ADC development, and capacity investment. Recent milestones include two Chinese lung cancer approvals in 2025 and the June 2026 bispecific approval.
Key companies profiled in the report include Daiichi Sankyo Company, Limited (Japan), AstraZeneca PLC (U.K.), F. Hoffmann-La Roche Ltd / Chugai Pharmaceutical Co., Ltd. (Switzerland/Japan), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Astellas Pharma Inc. (Japan), Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), RemeGen Co., Ltd. (China), Sichuan Baili Pharmaceutical Co., Ltd. / SystImmune (China), Duality Biologics (China), Hansoh Pharmaceutical Group Company Limited (China), Lepu Biopharma Co., Ltd. (China), Innovent Biologics, Inc. (China), LigaChem Biosciences Inc. (South Korea), Samsung Biologics Co., Ltd. (South Korea), Celltrion, Inc. (South Korea), WuXi XDC Cayman Inc. (China), and Zydus Lifesciences Limited (India).
The study covers medicines in which a monoclonal antibody carries a highly potent drug payload attached by a chemical linker, as sold across the region's markets. Products are analyzed by target, payload, linker, and format, and the report separates ADCs developed by multinational companies from those that originated in China, Japan, and South Korea. Market value is based on manufacturer sales of approved products, on the same basis as the Meticulous global ADC study.
Asia is both a major source of patients and a growing source of new ADCs, with roughly half of the about 20 million new cancer cases diagnosed worldwide in 2022 occurring in Asia, according to the International Agency for Research on Cancer, and breast, lung, and gastric cancers, all key ADC indications, are among the most common tumors in the region. Japan's Daiichi Sankyo created Enhertu and Datroway on its DXd platform, keeps exclusive rights to both in Japan, and makes them for global supply. China has moved from fast follower to innovator, with the first TROP2 ADC approval in lung cancer in March 2025 and, as reported in June 2026, the world's first bispecific ADC approval for izalontamab brengitecan from Sichuan Baili and SystImmune.
Market Dynamics
The region's cancer burden is large and rising as populations age, and EGFR-mutant lung cancer, which is far more frequent in Asian than in Western patients, has become a direct ADC target. A wave of domestic approvals in China from RemeGen, Kelun-Biotech, Hengrui, and Lepu Biopharma is adding lower-priced options. Reimbursement is widening access, as Enhertu's late-2024 national listing in China lifted volumes and Japan, South Korea, Taiwan, and Australia keep adding ADCs to their lists. Japan's ADC leadership through Daiichi Sankyo, Astellas, Takeda, and Chugai anchors the market, and upfront and milestone income from global partners is funding Asian pipelines.Value growth is held back by the deep price cuts that China's National Healthcare Security Administration requires for reimbursement listing, regular national health insurance price revisions in Japan, and the low launch prices of domestic Chinese ADCs. In poorer markets such as India, Indonesia, and Vietnam, most patients pay out of pocket, which limits use. High-potency payload synthesis and conjugation are complex and capacity is concentrated, and toxicities such as interstitial lung disease, which has shown higher incidence among Japanese patients treated with trastuzumab deruxtecan, require close monitoring. Other challenges are U.S. legislative scrutiny of Chinese biotechnology companies and contract manufacturers, crowding around HER2 and TROP2, biosimilar entry as early ADC patents expire, and the need for multiregional data, since U.S. regulators have been reluctant to accept trials run only in China.
Opportunities include out-licensing of Asian ADC assets to global drug makers, as seen in deals signed by SystImmune, Kelun-Biotech, Hansoh, Duality Biologics, and LigaChem Biosciences with Western partners. Contract manufacturing is expanding through WuXi XDC in China and Samsung Biologics and Celltrion in South Korea, bispecific and dual-payload ADCs are advancing fastest in Asian pipelines, and biosimilars, lower-cost domestic products, and public insurance schemes could open access in India, Southeast Asia, and Australia. Key trends include China's growing role as a world source of new ADCs, the first bispecific approval, development focused on lung, gastric, and nasopharyngeal cancers that are common in Asia, and the dominance of topoisomerase I payloads.
Segment Analysis
The report analyzes the Asia-Pacific ADC market by target, payload, linker, format, product origin, indication, end user, and country, helping stakeholders see where sales sit today and how domestic Asian products will shift them.By target, the study covers HER2, TROP2, Nectin-4, hematologic targets (CD30, CD79b, CD22, CD33, and BCMA), and EGFR/HER3 & emerging targets (B7-H3, c-Met, Claudin 18.2, and others). HER2 is expected to hold the largest share in 2026, supported by Enhertu's strong uptake in Japan and China following reimbursement listing, Kadcyla's established use, and domestic HER2 ADCs such as disitamab vedotin and trastuzumab rezetecan. EGFR/HER3 & emerging targets are expected to grow at the highest CAGR, driven by the June 2026 approval of the EGFR-HER3 bispecific izalontamab brengitecan and a deep pipeline of B7-H3, c-Met, and Claudin 18.2 candidates from Asian developers.
The payload analysis includes topoisomerase I inhibitors, microtubule inhibitors, DNA-damaging agents, and novel payloads. Topoisomerase I inhibitors are expected to lead in 2026, since Enhertu, Datroway, sacituzumab tirumotecan, and trastuzumab rezetecan all use this class, which kills nearby tumor cells with uneven target expression. Novel payloads are expected to grow at the highest CAGR, as Chinese and Korean developers test new payload classes and dual-payload designs to overcome resistance that builds up when similar ADCs are used one after another.
By linker, the report covers cleavable and non-cleavable linkers. Cleavable linkers are used in most recent launches in the region, including Enhertu, which relies on a tetrapeptide-based cleavable linker to release its DXd payload, and in the topoisomerase I-based products from Chinese developers. Non-cleavable linkers are used in established products such as Kadcyla and in biosimilar trastuzumab emtansine launched in India, giving this segment a stable base as biosimilar versions widen access.
By format, the market is divided into monospecific, bispecific, and dual-payload ADCs. Monospecific ADCs are expected to represent the largest share in 2026, because nearly every product now sold, from Enhertu to China's recent domestic launches, binds a single antigen. Bispecific ADCs are expected to grow at the highest CAGR, building on the first approval of a bispecific ADC in China in June 2026 and further Asian candidates that target two antigens to improve tumor selectivity and limit escape.
By product origin, the report covers multinational-originated ADCs and Asia-originated ADCs, with the latter split into China-, Japan-, and Korea-originated products. Multinational-originated ADCs are expected to hold the largest share in 2026, reflecting the broad use and reimbursement of Enhertu, Kadcyla, Padcev, Adcetris, and other established brands across Japan, China, South Korea, Australia, and Taiwan. Asia-originated ADCs are expected to grow at the highest CAGR, as China had approved five or more domestic ADCs by mid-2026, these products launch at lower prices, and they are steadily being added to reimbursement lists.
By indication, the study covers breast cancer (HER2-positive, HER2-low & HER2-ultralow, and triple-negative & HR-positive/HER2-negative), lung cancer (EGFR-mutant NSCLC, HER2-mutant NSCLC, and other NSCLC & SCLC), gastric cancer, urothelial cancer, hematologic malignancies, gynecologic cancers, and nasopharyngeal & other cancers. Breast cancer is expected to hold the largest share in 2026, as Enhertu, Kadcyla, Datroway, and sacituzumab tirumotecan are widely used across HER2-positive, HER2-low, and triple-negative disease. Lung cancer is expected to grow at the highest CAGR, driven by China's 2025 approvals in EGFR-mutant and HER2-mutant NSCLC and the high frequency of EGFR mutations among Asian patients.
By end user, the report covers public hospitals, private hospitals, and specialty cancer centers. Public hospitals are expected to account for the largest share in 2026, as public tertiary hospitals in China, Japan, and South Korea deliver most reimbursed cancer care, including Enhertu after its national listing in China. Specialty cancer centers are expected to grow at the highest CAGR, since ADC trials, toxicity management, and complex regimens are concentrated in leading centers, one of which, Shanghai Chest Hospital, ran the key trial for trastuzumab rezetecan.
Regional Analysis
The report covers Japan, China, South Korea, Australia & New Zealand, India, Taiwan, Singapore, Southeast Asia (Thailand, Malaysia, Indonesia, Vietnam, and the Philippines), and the Rest of Asia-Pacific. The country analysis considers cancer incidence, approval timing, reimbursement systems, pricing, local development and manufacturing, and patient access.Japan is expected to be the largest country market in the region in 2026, supported by universal health insurance, early approvals, high spending per patient, and Daiichi Sankyo's sole domestic rights to its two DXd brands. Astellas and Takeda co-market Padcev and Adcetris, and Chugai sells Roche's ADCs, giving Japan the most developed ADC market in Asia. South Korea is another important market, with national insurance coverage, active participation in global trials, and ADC know-how at LigaChem Biosciences, Samsung Biologics, and Celltrion.
China is expected to grow at the highest CAGR during the forecast period, driven by fast approval of domestic ADCs, reimbursement listing, and licensing income that funds further development. Australia & New Zealand offer steady growth through the Pharmaceutical Benefits Scheme and Pharmac, while India, which recorded about 1.46 million new cancer cases in 2022 according to the Indian Council of Medical Research, is growing from a smaller base as biosimilar trastuzumab emtansine and public insurance widen access. Taiwan, Singapore, and Southeast Asia add demand as reimbursement and cancer services expand.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, and 2025 market share/rank analysis, with company profiles grouped into multinational ADC companies, Asia-originated ADC developers, and manufacturers and biosimilar developers, each covering business overview, financials, product portfolio, strategic developments, and SWOT analysis.The market brings together multinational drug makers, Japan's Daiichi Sankyo and its peers, fast-growing Chinese developers, Korean technology and manufacturing firms, and contract manufacturers. Companies compete on clinical differentiation, speed of regional approval, reimbursement listing and pricing, manufacturing capacity, and global partnerships. Main strategies include label expansion, reimbursement listing, out-licensing, next-generation ADC development, and capacity investment. Recent milestones include two Chinese lung cancer approvals in 2025 and the June 2026 bispecific approval.
Key companies profiled in the report include Daiichi Sankyo Company, Limited (Japan), AstraZeneca PLC (U.K.), F. Hoffmann-La Roche Ltd / Chugai Pharmaceutical Co., Ltd. (Switzerland/Japan), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Astellas Pharma Inc. (Japan), Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), RemeGen Co., Ltd. (China), Sichuan Baili Pharmaceutical Co., Ltd. / SystImmune (China), Duality Biologics (China), Hansoh Pharmaceutical Group Company Limited (China), Lepu Biopharma Co., Ltd. (China), Innovent Biologics, Inc. (China), LigaChem Biosciences Inc. (South Korea), Samsung Biologics Co., Ltd. (South Korea), Celltrion, Inc. (South Korea), WuXi XDC Cayman Inc. (China), and Zydus Lifesciences Limited (India).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the Asia-Pacific ADC market through 2036.
- Explains how domestic approvals in China, reimbursement listing, and Japan's ADC leadership are shaping regional demand.
- Assesses the impact of reimbursement price cuts, unequal access, manufacturing complexity, and toxicity on market value.
- Identifies high-growth opportunities across target, payload, linker, format, product origin, indication, end user, and country.
- Tracks the rise of Asia-originated, bispecific, and novel-payload ADCs and their licensing to global partners.
- Benchmarks multinational and Asian ADC companies on portfolios, pipelines, partnerships, and manufacturing.
- Supports portfolio planning, business development, market access, and investment decisions for drug developers, CDMOs, and investors.
Key Questions Answered
- How large is the Asia-Pacific ADC market today, and how will it grow through 2036?
- How are China-originated ADCs and national reimbursement listing changing the regional market?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will reimbursement price cuts in China and price revisions in Japan affect market value?
- Which target, payload, linker, format, product origin, indication, and end user segments will grow the fastest?
- How quickly will bispecific and novel-payload ADCs be adopted in the region?
- Which countries offer the most attractive opportunities, and how will access improve in India and Southeast Asia?
- How are geopolitical pressures affecting licensing and manufacturing of China-origin ADCs?
- Who are the leading companies in the market, and how do they compare?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Asia-Pacific ADC Market, by Target
6. Asia-Pacific ADC Market, by Payload
7. Asia-Pacific ADC Market, by Linker
8. Asia-Pacific ADC Market, by Format
9. Asia-Pacific ADC Market, by Product Origin
10. Asia-Pacific ADC Market, by Indication
11. Asia-Pacific ADC Market, by End User
12. Asia-Pacific ADC Market, by Country
13. Competitive Landscape
14. Company Profiles
15. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Daiichi Sankyo Company, Limited
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd / Chugai Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Gilead Sciences, Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- RemeGen Co., Ltd.
- Sichuan Baili Pharmaceutical Co., Ltd. / SystImmune
- Duality Biologics
- Hansoh Pharmaceutical Group Company Limited
- Lepu Biopharma Co., Ltd.
- Innovent Biologics, Inc.
- LigaChem Biosciences Inc.
- Samsung Biologics Co., Ltd.
- Celltrion, Inc.
- WuXi XDC Cayman Inc.
- Zydus Lifesciences Limited
